0.29
-0.026(-8.34%)
Currency In USD
Address
960 San Antonio Road
Palo Alto, CA 94303
United States of America
Phone
650-516-4310
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
117
First IPO Date
March 05, 2021
| Name | Title | Pay | Year Born |
| Mr. Jaisim Shah | President, Chief Executive Officer & Director | 971,517 | 1960 |
| Mr. Suresh K. Khemani | Senior Vice President & Chief Commercial Officer | 456,820 | 1960 |
| Dr. Dmitri V. Lissin M.D. | Senior Vice President & Chief Medical Officer | 528,826 | 1959 |
| Mr. Stephen Ma | Senior Vice President, Chief Financial Officer & Corporate Secretary | 708,783 | 1973 |
| Dr. Henry H. Ji Ph.D. | Executive Chairman | 885,430 | 1964 |
| Ms. Gigi DeGuzman | Senior Executive Director & Chief of Staff | 0 | N/A |
| Mr. Mike Ciaffi | National Sales Director | 0 | N/A |
| Dr. Suketu D. Desai Ph.D. | Chief Technology Officer & Senior Vice President | 0 | 1966 |
| Mr. Steven F. Lincoln J.D. | General Counsel & Chief Compliance Officer | 0 | N/A |
| Mr. Sumant Rajendran | Executive Director of Marketing | 0 | N/A |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.